Search Results
Your search for ,maY matches 17173 pages
Showing 4351 - 4400Expert Point of View: Nilofer Azad, MD
Nilofer Azad, MD, Professor of Oncology at Johns Hopkins University School of Medicine and Co-Director of Cancer Genetics and Epigenetics at the Sidney Kimmel Comprehensive Cancer Center, Baltimore, was invited to discuss the results of the phase III TOPAZ-1 study, which found an overall survival...
Ivosidenib vs Placebo for Previously Treated Advanced IDH1-Mutated Cholangiocarcinoma: Final Overall Survival Analysis of the ClarIDHy Trial
As reported in JAMA Oncology by Andrew X. Zhu, MD, PhD, and colleagues, the final overall survival analysis of the pivotal phase III ClarIDHy trial showed prolonged overall survival with ivosidenib vs placebo in previously treated patients with unresectable or metastatic cholangiocarcinoma and an...
Adjuvant Nivolumab Improves Disease-Free Survival vs Placebo in Resected Esophageal or Gastroesophageal Junction Cancer After Neoadjuvant Chemoradiotherapy
As reported in The New England Journal of Medicine by Ronan J. Kelly, MB BCh, MBA, of The Charles A. Sammons Cancer Center at Baylor University Medical Center, and colleagues, an interim analysis of the phase III CheckMate 577 trial has shown a significant improvement in disease-free survival with ...
Expert Point of View: Gabriel A. Brooks, MPH, MD
Gabriel A. Brooks, MPH, MD, Associate Professor of Medicine, Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, was invited to discuss the results of the ACCENT/IDEA database analysis of early treatment discontinuation in stage III colon cancer. Although the results confirm the...
Adjuvant Therapy for Colon Cancer: Impact of Stopping Treatment Early
For patients with stage III colon cancer, early discontinuation of adjuvant chemotherapy leads to worse outcomes—but early discontinuation of oxaliplatin did not. These findings, which came from an analysis of the large ACCENT and IDEA clinical trials databases, were presented at the 2022 ASCO...
Expert Point of View: Rona Yaeger, MD
Rona Yaeger, MD, Assistant Attending Physician at Memorial Sloan Kettering Cancer Center, New York, offered her thoughts on the findings of Morris et al for the combination regimen of encorafenib, cetuximab, and nivolumab in microsatellite-stable BRAF V600E–mutated metastatic colorectal cancer...
KEYNOTE-811: Pembrolizumab Plus Trastuzumab and Chemotherapy in Previously Untreated Advanced HER2-Positive Gastric Adenocarcinoma
As reported in Nature by Yelena Y. Janjigian, MD, of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center, and colleagues, the first interim analysis of the phase III KEYNOTE-811 trial has shown a significantly higher objective response rate with the addition of...
Recent FDA Approvals in Gastrointestinal Cancer
Over the past year, the U.S. Food and Drug Administration granted approval to several novel drugs and new indications for older therapeutic agents used in gastrointestinal oncology. Cetuximab Plus Encorafenib On September 28, 2021, cetuximab (Erbitux) was approved in combination with encorafenib...
Expert Point of View: Benoit Rousseau, MD, PhD
Benoit Rousseau, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, called the findings of the phase II GERCOR NIPICOL trial “interesting and convincing.” Long-term follow-up showed the 3-year progression-free survival rate to be 70% after 1 total year of treatment with nivolumab plus...
NIPICOL Trial: Promising Outcomes With Shorter Duration of Checkpoint Inhibition in Metastatic Colorectal Cancer
The phase II GERCOR NIPICOL study evaluated 1 year of treatment with nivolumab plus ipilimumab in patients with chemotherapy-resistant metastatic colorectal cancer whose tumors were microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR). With this shortened treatment duration,...
Sotorasib in Previously Treated Patients With KRAS G12C–Mutant Colorectal Cancer
In a prespecified analysis of the phase II CodeBreaK100 trial reported in The Lancet Oncology, Marwan Fakih, MD, and colleagues found that the KRAS G12C protein inhibitor sotorasib showed modest activity in patients with previously treated KRAS G12C–mutant colorectal cancer.1 Study Details The...
Neoadjuvant Checkpoint Inhibitor Doublet Yields Complete Responses in Gastroesophageal Cancers
In patients with resectable microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) gastric and gastroesophageal junction adenocarcinoma, dual checkpoint inhibition with ipilimumab and nivolumab given as neoadjuvant therapy led to a pathologic complete response rate of 58.6%,...
Expert Point of View: Elena Élez, MD, PhD
Invited discussant of the two studies, Elena Élez, MD, PhD, of the Colon Cancer Program, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discussed the challenge of treating BRAF-mutant colorectal cancer and what the new data bring to that effort. Dr. Élez noted: “BRAF V600E–mutant...
Gastrointestinal Oncology 2021–2022 Almanac
The past year has seen unprecedented progress across the spectrum of gastrointestinal malignances, including the advancement of immunotherapy and targeted molecular agents and the refinement of adjuvant therapy using novel as well as existing therapies. Three themes emerging from these reports are: ...
New ASCO-SNO Guideline Addresses Treatment Recommendations Tailored to Glioma Subtypes
Reflecting recent significant classification changes and new data on the use of biomarkers to inform treatment for central nervous system tumors, a new guideline offers oncologists up-to-date recommendations for managing gliomas in adults with neurologic cancer.1 “Over the past decade, there have...
ASCO Provisional Clinical Opinion Offers Guidance for Using and Interpreting Genomic Testing in Patients With Advanced Cancer
Somatic genomic testing should be a routine part of clinical care for many patients with metastatic or advanced solid tumors, according to a new ASCO provisional clinical opinion.1 As reported in the Journal of Clinical Oncology, the expert panel found that genomic testing in oncology practice has...
Should Patients Aged 80 and Older Receive Single-Agent Immune Checkpoint Inhibitor Treatment?
The checkpoint inhibitors are among the most important advances in oncology in recent times. They have changed the natural history of many tumors, particularly melanoma. They have a favorable toxicity profile, which for most patients is manageable and tolerable. However, there are several...
Outcomes and Toxicity With Single-Agent Immune Checkpoint Inhibitor Treatment in Geriatric Patients With Cancer
In a multicenter international retrospective cohort study reported in JAMA Oncology, Caroline A. Nebhan, MD, PhD, of Vanderbilt University Medical Center, and colleagues found that single-agent immune checkpoint inhibitor therapy in patients with cancer aged 80 and older appeared to be effective...
Expert Point of View: Quynh-Thu Le, MD, FACR, FASTRO
According to Quynh-Thu Le, MD, FACR, FASTRO, Professor and Chair of Radiation Oncology at Stanford, these results suggest that monitoring circulating human papillomavirus (HPV) DNA may lead to the detection of relapse prior to imaging. In an interview with The ASCO Post, Dr. Le also noted that...
Blood Test Predicts Recurrence of HPV-Driven Oropharyngeal Cancer After Treatment
A blood-basedliquid biopsy may accurately predict recurrence of human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma following treatment, according to data presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.1 Results of the large, multi-institutional study...
Midtreatment Imaging De-escalates Therapy for Half of Study Patients With Oropharyngeal Cancer
Positron-emission tomography (PET) scans obtained before and midway through treatment may be used to de-escalate therapy for patients with oropharyngeal cancer, leading to fewer side effects, according to data presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.1 An interim...
Allogeneic Transplantation for Hematologic Neoplasms in Adults
“The value of experience is not in seeing much, but in seeing wisely.” —Sir William Osler To complement The ASCO Post’s continued comprehensive coverage of the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting...
Expert Point of View: E. Gabriela Chiorean, MD
The invited discussant of the CodeBreaK 100 data, E. Gabriela Chiorean, MD, Professor of Medicine at the University of Washington and Fred Hutchinson Cancer Research Center, and Clinical Director of the Gastrointestinal Medical Oncology program at Seattle Cancer Care Alliance, found the efficacy...
Expert Point of View: Hao G. Nguyen, MD, PhD
Invited discussant Hao G. Nguyen, MD, PhD, of the University of California, San Francisco, said: “New treatments are needed for advanced penile cancer. PERICLES is the first randomized trial for patients with stage IV penile cancer treated without chemotherapy. Although this prospective trial...
Expert Point of View: Xin Gao, MD
Xin Gao, MD, of Harvard Medical School and Massachusetts General Hospital Cancer Center, commented on this study: “ARIES is a phase II study evaluating the anti–PD-L1 therapy avelumab in cisplatin-ineligible advanced urothelial cancer patients with a PD-L1 expression of at least 5% on tumor cells...
Expert Point of View: Elisabeth I. Heath, MD, FACP, and Oliver Sartor, MD
Formal discussant of the ARASENS trial, Elisabeth I. Heath, MD, FACP, Professor of Oncology and Associate Center Director, Translational Sciences, at Karmanos Cancer Institute in Detroit, commented on the changing paradigm in prostate cancer treatment. “The narrative is changing to triplet therapy, ...
Expert Point of View: Guru P. Sonpavde, MD
Invited discussant Guru P. Sonpavde, MD, Director of the Bladder Cancer Program at Dana-Farber Cancer Institute, said: “Antibody-drug conjugates are a major weapon in the way forward in bladder cancer…. The EV-103 trial evaluated neoadjuvant therapy with enfortumab vedotin-ejfv, one of two...
Study Reports Modest Gain in Progression-Free Survival With Continued Enzalutamide in Advanced Prostate Cancer
Enzalutamide is a common first-line choice for patients with metastatic castration-resistant prostate cancer, but response in some patients eventually wanes and then patients are switched to a different treatment. According to the phase IIIb PRESIDE trial, reported at the 2022 ASCO Genitourinary...
CheckMate 9ER: Final Results Support First-Line Regimen of Nivolumab Plus Cabozantinib in Advanced Kidney Cancer
The combination of nivolumab plus cabozantinib achieved a continued survival benefit compared with sunitinib in patients with untreated clear cell metastatic or advanced renal cell carcinoma, according to a final overall survival analysis of the phase III CheckMate 9ER trial.1 Additionally,...
Olaparib With or Without Cediranib vs Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer
As reported in the Journal of Clinical Oncology by Joyce F. Liu, MD, and colleagues, the phase III NRG-GY004 trial has shown no significant improvement in progression-free survival with olaparib/cediranib vs platinum-based chemotherapy in patients with recurrent platinum-sensitive ovarian cancer....
Study Identifies Genetic Variants That May Contribute to Accelerated Aging in Childhood Cancer Survivors
Scientists from St. Jude Children’s Research Hospital have identified variants in two genes that may be associated with accelerated aging in childhood cancer survivors. Their research looked at the difference between the survivors’ biologic age and chronologic age. The study, published by Dong et...
FDA Approves Radioligand for Metastatic Castration-Resistant Prostate Cancer
On March 23, the U.S. Food and Drug Administration approved lutetium Lu-177 vipivotide tetraxetan (Pluvicto) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor...
HRR Mutational Status May Be Prognostic of Survival Outcomes for Women With Recurrent Platinum-Sensitive Ovarian Cancer
Results of a biomarker analysis of the NRG Oncology NRG-GY004 trial were presented during the Society for Gynecologic Oncology’s (SGO) Annual Meeting on Women’s Cancer. The analysis, which occurred as part of a preplanned translational endpoint for the study, concluded that homologous recombination ...
Younger Patients With Appendicitis May Be at Increased Risk for Appendiceal Cancer
Although appendectomy is still the most effective treatment for acute appendicitis, nonoperative management is increasingly common, as recent studies—such as one published in November 2020 in The New England Journal of Medicine and a second published in December 2021 in the same journal—have shown...
PARP Inhibitors in the Treatment of Breast Cancer: What’s Next?
In patients with breast cancer tumors harboring BRCA1 and BRCA2 mutations, inhibitors of poly (ADP-ribose) polymerase (PARP) have emerged as essential therapeutic agents. What more needs to be done to obtain even more benefit from these targeted agents? This question was tackled at the 2022 Miami...
Characteristics of Nonalcoholic Fatty Liver Disease–Related HCC vs HCC From Other Causes
In a meta-analysis reported in The Lancet Oncology, Tan et al found that patients with nonalcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (HCC) were more likely to have metabolic/cardiovascular comorbidity, less likely to have cirrhosis, and less likely to undergo...
Michelle Mierzwa, MD, on Oropharyngeal Cancer: Early Results on De-escalated Radiotherapy
Michelle Mierzwa, MD, of the University of Michigan, discusses early findings from a phase II trial of FDG-PET (fluorodeoxyglucose–positron-emission tomography) de-escalated radiotherapy for patients with p16-positive orophyaryngeal cancer. An interim analysis suggests that for approximately half...
Adjuvant Pembrolizumab May Improve Disease-Free Survival in Patients With Early-Stage NSCLC
Adjuvant pembrolizumab may improve disease-free survival compared to placebo in patients with early-stage non–small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy when indicated, investigators from the PEARLS/KEYNOTE-091 trial reported in a European Society for...
Researchers Identify Trends in Treatment for Retroperitoneal Soft-Tissue Sarcoma
Researchers have published an analysis of strategies for treating retroperitoneal soft-tissue sarcoma, which has historically been understudied due to its rarity. The researchers say the trends they identified—particularly the convergence of certain treatments across centers—will help guide the way ...
Lung Cancer Diagnosis With Low-Dose CT Screening and a Program for Management of Incidentally Detected Lung Nodules
In the prospective observational DELUGE study reported in the Journal of Clinical Oncology, researchers in the Baptist Memorial Health Care Corporation (BMHCC) found that programs for low-dose computed tomography (CT) screening and for management of incidentally detected lung nodules were...
Temozolomide Followed by Low-Dose Ipilimumab/Nivolumab in MSS and MGMT-Silenced Metastatic Colorectal Cancer
In an Italian phase II study (MAYA) reported in the Journal of Clinical Oncology, Morano et al found that patients with microsatellite-stable (MSS) and O6-methylguanine–DNA methyltransferase (MGMT)-silenced metastatic colorectal cancer without disease progression on temozolomide derived benefit...
FDA Approves Nivolumab/Relatlimab-rmbw for Unresectable or Metastatic Melanoma
On March 18, the U.S. Food and Drug Administration (FDA) approved nivolumab and relatlimab-rmbw (Opdualag) for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. The approved treatment is a fixed-dose combination of the LAG-3–blocking antibody relatlimab ...
Half of Patients With Cancer and Survivors Report Incurring Cancer-Related Medical Debt
The cost of cancer care is substantially impacting the lives of patients with cancer and survivors, forcing them to make significant lifestyle changes and causing some to incur long-term medical debt. According to a new Survivor Views survey from the American Cancer Society Cancer Action Network...
Antibody Response to SARS–CoV-2 mRNA-1273 Vaccination in Patients With Cancer: Single-Institution Study
In a single-institution study reported in JAMA Oncology, Giuliano et al found that seroconversion after two doses of the SARS–CoV-2 mRNA-1273 (Moderna) vaccine in patients with cancer was lower among patients with hematologic malignancies vs solid tumors and differed according to cancer treatment...
Trends in Grade 5 Toxicity and Response Rates in Phase I Trials for Hematologic Malignancies
In a study reported in the Journal of Clinical Oncology, Chihara et al found that rates of grade 5 toxicity have remained low and that rates of overall and complete response have increased over time in phase I trials for patients with hematologic malignancies sponsored by the National Cancer...
Study Reports Modest Gain in Progression-Free Survival With Continued Enzalutamide in Advanced Prostate Cancer
Enzalutamide is a common first-line choice for patients with metastatic castration-resistant prostate cancer, but response in some patients eventually wanes and then patients are switched to a different treatment. According to the phase IIIb PRESIDE trial, reported at the 2022 ASCO Genitourinary...
Expert Point of View: Elisabeth I. Heath, MD, FACP, and Oliver Sartor, MD
Formal discussant of the ARASENS trial, Elisabeth I. Heath, MD, FACP, Professor of Oncology and Associate Center Director, Translational Sciences, at Karmanos Cancer Institute in Detroit, commented on the changing paradigm in prostate cancer treatment. “The narrative is changing to triplet therapy, ...
PARP Inhibitor Plus Abiraterone Benefits Subgroups of Patients With Metastatic Castration-Resistant Prostate Cancer
The combination of the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib plus abiraterone acetate and prednisone as first-line therapy significantly improved radiographic progression-free survival vs abiraterone and placebo alone in men with metastatic castration-resistant prostate cancer...
Shorter-Course Radiation Therapy: A New Practice Standard After Prostatectomy?
Hypofractionated radiotherapy to the prostate bed proved to be noninferior to conventionally fractionated radiotherapy after prostatectomy regarding gastrointestinal and genitourinary side effects, according to the results of the phase III NRG Oncology GU003 trial, presented at the 2021 American...
STAMPEDE: In Nonmetastatic Castration-Sensitive Prostate Cancer, Abiraterone Added to Androgen-Deprivation Therapy Improves Survival
The addition of 2 years of abiraterone acetate plus prednisolone (AAP) to androgen-deprivation therapy improves metastasis-free survival and overall survival compared with androgen-deprivation therapy alone in men with nonmetastatic castration-sensitive prostate cancer, according to a primary...
